The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 09, 2014

Filed:

Sep. 03, 2009
Applicants:

Isabel Kalofonos, Cambridge, MA (US);

G. Patrick Stahly, West Lafayette, IN (US);

William Martin-doyle, Cambridge, MA (US);

Dimitris Kalofonos, Cambridge, MA (US);

Jeffrey S. Stults, West Lafayette, IN (US);

Travis L. Houston, Lafayette, IN (US);

Inventors:

Isabel Kalofonos, Cambridge, MA (US);

G. Patrick Stahly, West Lafayette, IN (US);

William Martin-Doyle, Cambridge, MA (US);

Dimitris Kalofonos, Cambridge, MA (US);

Jeffrey S. Stults, West Lafayette, IN (US);

Travis L. Houston, Lafayette, IN (US);

Assignee:

Bionevia, LLC, Concord, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/427 (2006.01); A61P 9/10 (2006.01); A61P 27/12 (2006.01); C07D 277/36 (2006.01);
U.S. Cl.
CPC ...
C07D 277/36 (2013.01); A61K 31/427 (2013.01);
Abstract

The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.


Find Patent Forward Citations

Loading…